Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8T81

Influenza PAN endonuclease E23K mutant with 6-(4-(1H-tetrazol-5-yl)-2-(trifluoromethyl)phenyl)-3-hydroxy-4-oxo-1,4-dihydropyridine-2-carboxylic acid

Summary for 8T81
Entry DOI10.2210/pdb8t81/pdb
Related8T5V 8T5W 8T5Z 8T67 8T6Z
DescriptorPolymerase acidic protein, MANGANESE (II) ION, (6M)-3-hydroxy-4-oxo-6-[(4M)-4-(1H-tetrazol-5-yl)-2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-2-carboxylic acid, ... (4 entities in total)
Functional Keywordsinfluenza endonuclease, resistance, drug discovery, metal-binding pharmacophore, viral protein, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological sourceInfluenza A virus
Total number of polymer chains1
Total formula weight22901.73
Authors
Kohlbrand, A.J.,Cohen, S.M. (deposition date: 2023-06-21, release date: 2024-05-08)
Primary citationKohlbrand, A.J.,Stokes, R.W.,Sankaran, B.,Cohen, S.M.
Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants.
Biochemistry, 63:264-272, 2024
Cited by
PubMed Abstract: Vital to the treatment of influenza is the use of antivirals such as Oseltamivir (Tamiflu) and Zanamivir (Relenza); however, antiviral resistance is becoming an increasing problem for these therapeutics. The RNA-dependent RNA polymerase acidic N-terminal (PA) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target that was recently validated with the approval of Baloxavir Marboxil (BXM). Despite its clinical success, BXM has demonstrated susceptibility to resistance mutations, specifically the I38T, E23K, and A36 V mutants of PA. To better understand the effects of these mutations on BXM resistance and improve the design of more robust therapeutics, this study examines key differences in protein-inhibitor interactions with two inhibitors and the I38T, E23K, and A36 V mutants. Differences in inhibitor binding were evaluated by measuring changes in binding to PA using two biophysical methods. The binding mode of two distinct inhibitors was determined crystallographically with both wild-type and mutant forms of PA. Collectively, these studies give some insight into the mechanism of antiviral resistance of these mutants.
PubMed: 38190441
DOI: 10.1021/acs.biochem.3c00536
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon